trial

Valproate in Late Life Schizophrenia

NCTId NCT00194025
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 20 (actual)
Sponsored by University Hospitals Cleveland Medical Center
Primary completion 2006-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2004-11
Primary completion
2006-11
Eligibility
ALL · 50 Years

Interventions & indications

Drugs
Valproate

Sponsors

University Hospitals Cleveland Medical CenterLead Sponsor
Abbott Medical DevicesCollaborator

Investigators

1
Martha Sajatovic, MDPrincipal Investigator

Sites

1 total
Cleveland, United States

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE4
Primary Completion Date
2006-11
Status
COMPLETED
relationships
The graph out of here
drug
Valproate
drug
lead_sponsor
University Hospitals Cleveland Medical Center
company
collaborator
Abbott Medical Devices
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Martha Sajatovic, MD
person